+65 3158 9940
1300 798 820
+64 9801 0299
First ovarian cancer therapy for ST oncology portfolio Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone1 Phase 3 results expected in 2025 Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam Singapore and Seoul, South Korea, 13 October 2023: Independent
Singapore’s Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 Singapore, 8 May 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is
Sarcoma Medical Education – Liposarcoma by Bernd Kasper, MD, PhD This audio is intended for healthcare professionals for informative purposes only. Click play above to hear Bernd Kasper MD, PhD provide an overview of Liposarcoma.
Sarcoma Medical Education – Uterine Leiomyosarcoma (ULMS) Podcast by Giovanni Grignani, M.D. This audio is intended for healthcare professionals for informative purposes only. Click play above to hear Giovanni Grignani M.D. provide an overview of Uterine Leiomyosarcoma (ULMS).
These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch the Q&A panel discussion with Dr Paul Mitchell, Dr Santiago Ponce-Aix, Dr Amit Jain and Dr Tanujaa Rajasekaran. SCLC Webinar Chapters Q1: Does the 3-year OS data from CASPIAN influence the long-term efficacy perception of IO
These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Amit Jain discuss the treatment landscape and challenges in treating SCLC. SCLC Webinar Chapters Introduction – Dr Amit Jain Paradigms in Treatment of Extensive SCLC SCLC – A Challenging Disease Chemotherapy in 1st and
These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Santiago Ponce-Aix outline SCLC post-progression therapy options. SCLC Webinar Chapters Introduction for Dr Ponce-Aix New Standard of Care for ES-SCLC Retreatment with Platinum as 2nd line (>90 days) Immunotherapy in 2nd line Biomarker
These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Paul Mitchell provide an overview of the SCLC treatment landscape in Australia. SCLC Webinar Chapters Introduction: Dr Paul Mitchell Background: Small Cell Lung Cancer IMpower 133: Atezolizumab + Carboplatin + etoposide in 1L
These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch the complete webinar. SCLC Webinar Chapters Dr Paul Mitchell 2:31 to 3:03 Introduction: Dr Paul Mitchell 3:24 to 5:33 Background: Small Cell Lung Cancer 5.34 to 9.07 IMpower 133: Atezolizumab
This info is for Healthcare Practitioners only. Please contact ST at customerservice@stbiopharma.com if you need access to this page.